相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease
Renea Jablonski et al.
CHEST (2020)
Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease
Masataka Kuwana et al.
MODERN RHEUMATOLOGY (2020)
Myofascia-dominant involvement on whole-body MRI as a risk factor for rapidly progressive interstitial lung disease in dermatomyositis
Kohei Karino et al.
RHEUMATOLOGY (2020)
Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease The FLAIR Model
Xinyue Lian et al.
CHEST (2020)
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Athol U Wells et al.
Lancet Respiratory Medicine (2020)
Reduced miR-146a Promotes REG3A Expression and Macrophage Migration in Polymyositis and Dermatomyositis
Tingwang Jiang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients
Yuhui Li et al.
FRONTIERS IN MEDICINE (2020)
Mortality trends in polymyositis and dermatomyositis: A general population-based study
Lingyi Li et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients
Eun Ha Kang et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD
Yasuoki Horiike et al.
RHEUMATOLOGY (2019)
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases
Feng Liu et al.
CLINICAL SCIENCE (2019)
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Lutz Wollin et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Lung Diseases in Inflammatory Myopathies
Thomas Barba et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies
Michael Mahler et al.
FRONTIERS IN IMMUNOLOGY (2019)
Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events
Elisabeth Bendstrup et al.
RESPIRATION (2019)
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Farzan Solimani et al.
FRONTIERS IN IMMUNOLOGY (2019)
Chronic intermittent hypoxia worsens bleomycin-induced lung fibrosis in rats
Rudolf K. Braun et al.
RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY (2018)
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
Jose Antonio Rodriguez-Portal
DRUGS IN R&D (2018)
Response to: 'Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice' by Hocevar et al
Ingrid E. Lundberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Nintedanib for the treatment of idiopathic pulmonary fibrosis
Francesco Varone et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Update on outcome assessment in myositis
Lisa G. Rider et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece
Argyrios Tzouvelekis et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Eva Brunnemer et al.
RESPIRATION (2018)
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis
Sergio Harari et al.
RESPIRATION (2018)
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis
Adam Schiffenbauer et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies
Christopher A. Mecoli et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies
Kuberaka Mariampillai et al.
JAMA NEUROLOGY (2018)
Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
Pilar Rivera-Ortega et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
Shaney L. Barratt et al.
RESPIRATORY RESEARCH (2018)
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Martin Kolb et al.
THORAX (2017)
Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis
Siamak Moghadam-Kia et al.
JOURNAL OF RHEUMATOLOGY (2017)
Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis
Yoshiyuki Abe et al.
RHEUMATOLOGY (2017)
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Hannah Toellner et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Jingang Huang et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
Ulrich Costabel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report
Harold R. Collard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
Francesco Bonella et al.
RESPIRATION (2016)
Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease
Hironao Hozumi et al.
RESPIRATORY MEDICINE (2016)
High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis
Fumiko Tomiyama et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Increased Serum LIGHT Levels Correlate with Disease Progression and Severity of Interstitial Pneumonia in Patients with Dermatomyositis: A Case Control Study
Takuya Kotani et al.
PLOS ONE (2015)
Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer
Toshihiko Sato et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies
Lenka Plestilova et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis
Lutz Wollin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Tyrosine kinases in inflammatory dermatologic disease
Ricardo T. Paniagua et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis
Andrew L. Mammen
NATURE REVIEWS NEUROLOGY (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interstitial Lung Disease in Idiopathic Inflammatory Myopathy
Lesley Ann Saketkoo et al.
CURRENT RHEUMATOLOGY REVIEWS (2010)
Clinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis
Hiroshi Mukae et al.
CHEST (2009)
Interstitial lung disease in polymyositis and dermatomyositis: Longitudinal evaluation by pulmonary function and radiology
Maryam Fathi et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Interstitial lung diseases associated with amyopathic dermatomyositis
T. Suda et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis
S Sato et al.
ARTHRITIS AND RHEUMATISM (2005)
Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis
M Fathi et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
DA Isenberg et al.
RHEUMATOLOGY (2004)
分享论文
